Journal
APPLIED SURFACE SCIENCE
Volume 487, Issue -, Pages 807-818Publisher
ELSEVIER
DOI: 10.1016/j.apsusc.2019.05.099
Keywords
ZnO nanoparticles; Ovarian cancer; p53 mutation; Oxidative stress; Proteotoxic stress
Categories
Funding
- NIH [NIH-CA181808, DK56338, CA125123]
- CPRIT [RP150578]
- Dan L. Duncan Cancer Center
- John S. Dunn Gulf Coast Consortium for Chemical Genomics
Ask authors/readers for more resources
Ovarian cancer continues to be the most lethal among gynecological malignancies and the major cause for cancer-associated mortality among women. Limitations of current ovarian cancer therapeutics are highlighted by the high frequency of drug-resistant recurrent tumors and the extremely poor 5-year survival rates. Zinc oxide nanoparticles (ZnO-NPs) have shown promise in various biomedical applications including utility as anti-cancer agents. Here, we describe the synthesis and characterization of physical properties of ZnO-NPs of increasing particle size (15 nm-55 nm) and evaluate their benefits as an ovarian cancer therapeutic using established human ovarian cancer cell lines. Our results demonstrate that the ZnO-NPs induce acute oxidative and proteotoxic stress in ovarian cancer cells leading to their death via apoptosis. The cytotoxic effect of the ZnO-NPs was found to increase slightly with a decrease in nanoparticle size. While ZnO-NPs caused depletion of both wild-type and gain-of-function (GOF) mutant p53 protein in ovarian cancer cells, their ability to induce apoptosis was found to be independent of the p53-mutation status in these cells. Taken together, these results highlight the potential of ZnO-NPs to serve as an anti-cancer therapeutic agent for treating ovarian cancers independent of the p53 mutants of the cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available